Cargando…

Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center

PURPOSE: Heart transplanted recipients are at a high risk for COVID19 infection. Clinical presentation, complications, and related outcomes have been described worldwide. However, there is a paucity of data in Latin America. METHODS: Retrospective cohort of heart transplanted recipients followed at...

Descripción completa

Detalles Bibliográficos
Autores principales: Scolari, F.L., Hastenteufel, L.C., Einsfeld, L., Orlandin, L., Bueno, J., Clausell, N., Goldraich, L.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988607/
http://dx.doi.org/10.1016/j.healun.2022.01.813
_version_ 1784682999621615616
author Scolari, F.L.
Hastenteufel, L.C.
Einsfeld, L.
Orlandin, L.
Bueno, J.
Clausell, N.
Goldraich, L.A.
author_facet Scolari, F.L.
Hastenteufel, L.C.
Einsfeld, L.
Orlandin, L.
Bueno, J.
Clausell, N.
Goldraich, L.A.
author_sort Scolari, F.L.
collection PubMed
description PURPOSE: Heart transplanted recipients are at a high risk for COVID19 infection. Clinical presentation, complications, and related outcomes have been described worldwide. However, there is a paucity of data in Latin America. METHODS: Retrospective cohort of heart transplanted recipients followed at a center in Rio Grande do Sul, Brazil, between March 1st 2020 to October 1st 2021. Data are presented as absolute numbers (percentage) or median (interquartile). RESULTS: Among 62 recipients in follow-up, 21 (34%) were infected by COVID19. 58 (36-63) years, 67% male, body mass index of 26 kg/m², 48% with hypertension, 43% with chronic kidney disease, 5% diabetes, 3.1 (1.0-4.2) years post-transplant. Most common symptoms at presentation were fever (62%), myalgia (33%), cough (33%), and headache (33%). Dyspnea occurred in only 19% patients. Hospitalization was required for 13 (62%) with a time from symptoms onset to admission of 5 (1-12) days. In 38%, supplementary oxygen was needed, 19% required intensive care, and 10% mechanical ventilation. Main complications were bacterial pneumonia (38%), renal replacement therapy (19%), sepsis (10%), venous thromboembolism (10%), and pancreatitis (5%). Immunosuppression therapy was modified in 48% (in majority 89%, reduced). Median hospitalization time was 17 (8-28) days. Two (10%) patients died in hospital due to refractory hypoxemia and multiorgan dysfunction. The prevalence of COVID19 among heart transplanted patients was comparable to the general population in the state of Rio Grande do Sul (Figure 1) with a peak in December 2020. CONCLUSION: COVID19 infection prevalence among heart transplanted recipients was elevated, presenting mostly with typical symptoms, and frequent hospitalizations, supplementary oxygen requirement, and complications. Although the COVID19 prevalence in Latin America was amongst the highest reported, in-hospital mortality among infected heart transplanted recipients was similar to previously published data worldwide.
format Online
Article
Text
id pubmed-8988607
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-89886072022-04-11 Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center Scolari, F.L. Hastenteufel, L.C. Einsfeld, L. Orlandin, L. Bueno, J. Clausell, N. Goldraich, L.A. J Heart Lung Transplant (792) PURPOSE: Heart transplanted recipients are at a high risk for COVID19 infection. Clinical presentation, complications, and related outcomes have been described worldwide. However, there is a paucity of data in Latin America. METHODS: Retrospective cohort of heart transplanted recipients followed at a center in Rio Grande do Sul, Brazil, between March 1st 2020 to October 1st 2021. Data are presented as absolute numbers (percentage) or median (interquartile). RESULTS: Among 62 recipients in follow-up, 21 (34%) were infected by COVID19. 58 (36-63) years, 67% male, body mass index of 26 kg/m², 48% with hypertension, 43% with chronic kidney disease, 5% diabetes, 3.1 (1.0-4.2) years post-transplant. Most common symptoms at presentation were fever (62%), myalgia (33%), cough (33%), and headache (33%). Dyspnea occurred in only 19% patients. Hospitalization was required for 13 (62%) with a time from symptoms onset to admission of 5 (1-12) days. In 38%, supplementary oxygen was needed, 19% required intensive care, and 10% mechanical ventilation. Main complications were bacterial pneumonia (38%), renal replacement therapy (19%), sepsis (10%), venous thromboembolism (10%), and pancreatitis (5%). Immunosuppression therapy was modified in 48% (in majority 89%, reduced). Median hospitalization time was 17 (8-28) days. Two (10%) patients died in hospital due to refractory hypoxemia and multiorgan dysfunction. The prevalence of COVID19 among heart transplanted patients was comparable to the general population in the state of Rio Grande do Sul (Figure 1) with a peak in December 2020. CONCLUSION: COVID19 infection prevalence among heart transplanted recipients was elevated, presenting mostly with typical symptoms, and frequent hospitalizations, supplementary oxygen requirement, and complications. Although the COVID19 prevalence in Latin America was amongst the highest reported, in-hospital mortality among infected heart transplanted recipients was similar to previously published data worldwide. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988607/ http://dx.doi.org/10.1016/j.healun.2022.01.813 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle (792)
Scolari, F.L.
Hastenteufel, L.C.
Einsfeld, L.
Orlandin, L.
Bueno, J.
Clausell, N.
Goldraich, L.A.
Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center
title Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center
title_full Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center
title_fullStr Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center
title_full_unstemmed Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center
title_short Impact of COVID19 Infection Among Heart Transplanted Recipients: The Experience of a Latin American Center
title_sort impact of covid19 infection among heart transplanted recipients: the experience of a latin american center
topic (792)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988607/
http://dx.doi.org/10.1016/j.healun.2022.01.813
work_keys_str_mv AT scolarifl impactofcovid19infectionamonghearttransplantedrecipientstheexperienceofalatinamericancenter
AT hastenteufellc impactofcovid19infectionamonghearttransplantedrecipientstheexperienceofalatinamericancenter
AT einsfeldl impactofcovid19infectionamonghearttransplantedrecipientstheexperienceofalatinamericancenter
AT orlandinl impactofcovid19infectionamonghearttransplantedrecipientstheexperienceofalatinamericancenter
AT buenoj impactofcovid19infectionamonghearttransplantedrecipientstheexperienceofalatinamericancenter
AT clauselln impactofcovid19infectionamonghearttransplantedrecipientstheexperienceofalatinamericancenter
AT goldraichla impactofcovid19infectionamonghearttransplantedrecipientstheexperienceofalatinamericancenter